Article

Bravizine: A β-Arrestin–Biased Partial Agonist Targeting Dopamine D2 Receptor Hypersensitivity in Tardive Dyskinesia

2025-11-07

Abstract excerpt

<title>Abstract</title> <p> Tardive dyskinesia (TD) arises from chronic dopamine D2 receptor (D2R) blockade, leading to receptor hypersensitization and maladaptive downstream signaling. To address this, we designed Bravizine, a novel -arrestin–biased partial agonist, using an AI-augmented ligand optimization workflow built on REINVENT 4 with custom scoring functions for receptor bias prediction, docking affinity...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1460bde3-df8d-5935-bff2-ef53690273ca
DOI: 10.21203/rs.3.rs-8042007/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Bravizine: A β-Arrestin–Biased Partial Agonist Targeting Dopamine D2 Receptor Hypersensitivity in Tardive DyskinesiaDOI 10.21203/rs.3.rs-8042007/v1Read

Bravizine: A β-Arrestin–Biased Partial Agonist Targeting Dopamine D2 Receptor Hypersensitivity in Tardive DyskinesiaSemantic proximity Read

A small molecule enhances arrestin-3 binding to the β <sub>2</sub> -adrenergic receptorSemantic proximity Read

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor.Semantic proximity Read

A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity.Semantic proximity Read

Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs.Semantic proximity Read

BravizineDSE: A Multi-Input Deep Transformer for Receptor-Context-Aware GPCR Signaling Bias Prediction and Derivation of a Six-Feature Molecular Selectivity RuleSemantic proximity Read

Discovery of Selective Small-Molecule Ligands of SV2C by AI-Enhanced Virtual Screening and Experimental ValidationSemantic proximity Read

Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptorSemantic proximity Read

β-Arrestins and disease-linked variants: opportunities for targeted modulation.Semantic proximity Read

Hidden Bias: GPCR Polymorphisms and the Genomic Landscape of β-Arrestin SignalingSemantic proximity Read

Structural Genomics of the Human Dopamine Receptor SystemSemantic proximity Read

The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.Semantic proximity Read